NanoViricides to Present at D. Boral Capital Global Conference as Lead Drug Candidate Advances Toward Phase II Trials

NanoViricides, Inc. (NYSE American: NNVC) announced its participation in the D. Boral Capital Global Conference on May 7, 2026, at The Plaza Hotel in New York City. Anil R. Diwan, Ph.D., president and executive chairman, will host one-on-one meetings with investors and interested parties from 9:45 a.m. to 2:45 p.m. ET, according to a press release here.

The announcement comes as the clinical-stage biopharmaceutical company focuses on advancing its lead drug candidate, NV-387, a broad-spectrum antiviral designed to treat respiratory viral infections including RSV, COVID-19, Long COVID, Influenza, and other respiratory viruses. NV-387 has also demonstrated effectiveness in animal models for Monkeypox (MPox), Smallpox, and Measles. The drug recently completed a Phase I human clinical trial in healthy volunteers with no reported adverse events, and the company is now preparing to move NV-387 into Phase II human clinical trials.

“NV-387 is a unique broad-spectrum antiviral that we plan to develop as a treatment for multiple viral infections,” the company stated in its release. The drug’s potential to address a wide range of viruses positions it as a possible therapeutic for current and future viral threats.

In addition to NV-387, NanoViricides is developing NV-HHV-1 for the treatment of all Herpesvirus infections, including HSV-1 “cold sores,” HSV-2 “genital ulcers,” VZV Shingles, and Chickenpox. However, the company noted that it cannot project an exact date for filing an Investigational New Drug (IND) application for any of its drugs due to dependence on external collaborators and consultants.

The D. Boral Capital Global Conference provides an opportunity for NanoViricides to engage with potential investors as it seeks funding to advance its clinical pipeline. The company’s participation underscores its need for capital to support the costly Phase II trials, which are critical for regulatory approval and eventual commercialization.

NanoViricides specializes in creating special purpose nanomaterials for antiviral therapy, a novel approach that could offer advantages over traditional small-molecule drugs. The success of NV-387 in Phase I trials, with a favorable safety profile, is a positive signal for the company’s technology platform. However, the path to market remains uncertain, and the company will need to demonstrate efficacy in larger, randomized trials.

For investors, the conference represents a chance to assess NanoViricides’ progress and strategy. The company’s stock, traded on the NYSE American under the ticker NNVC, may see volatility based on updates from the event. As the company continues to navigate the clinical development process, its ability to secure partnerships or additional funding will be key factors to watch.

More information about NanoViricides is available in its newsroom here.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is NanoViricides to Present at D. Boral Capital Global Conference as Lead Drug Candidate Advances Toward Phase II Trials.

The post NanoViricides to Present at D. Boral Capital Global Conference as Lead Drug Candidate Advances Toward Phase II Trials appeared first on citybuzz.